Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | FDPS | P14324 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692498 | 1.00 | SNCA (0.74) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL19918301 | 0.88 | SNCA (0.80) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL25275685 | 0.88 | SNCA (0.80) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL14229893 | 0.85 | KDM4E (0.86) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| Boropinic Acid SCHEMBL16792175 | 0.84 | PTGES (0.81) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL30966315 | 0.83 | KDM4E (0.80) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL30482666 | 0.83 | KDM4E (0.77) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL3690899 | 0.83 | KDM4E (0.80) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL3690896 | 0.83 | KDM4E (0.80) | SNCAKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL25222797 | 0.83 | KDM4E (0.77) | SNCAKDM4EALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188878-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2020-06-18 | — | — | US | disclosed |
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-10-06 | — | — | US | disclosed |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2012-03-01 | — | — | US | disclosed |
| EP-2391658-A1 | MOLECULARLY IMPRINTED POLYMERS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2011-12-07 | — | — | EP | disclosed |
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2010085851-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-08-05 | — | — | WO | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | SNCA 4492/4885KDM4E 738/4885ALDH1A1 1036/4885 |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | SNCA 4492/4885KDM4E 738/4885ALDH1A1 1036/4885 |
| US-20200188878-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | SNCA 4492/4885KDM4E 738/4885ALDH1A1 1036/4885 |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | SNCA 4048/4885KDM4E 3045/4885ALDH1A1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.